Trial Profile

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FG 3246 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Fortis Therapeutics

Most Recent Events

28 Mar 2025 According to a FibroGen media release, company announced the peer-reviewed publication of this trial in the Journal of Clinical Oncology.
02 Apr 2024 Results published in a FibroGen media release.
02 Apr 2024 According to a FibroGen media release, announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com